Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Highlights: Record Growth and Profitability ... [Yahoo! Finance]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Revenue: $306 million, representing 64% year-over-year growth. Gross Margin: 61%, with a gross margin on Carvicti net product sales of 57%. Operating Margin: Improved from 142% in Q2 2023 to 6% in Q4 2025. Carvicti Net Trade Sales: $555 million in Q4 2025, a 66% increase year-over-year. US Net Trade Sales: $420 million, a 38% increase year-over-year. International Sales: $135 million, over a threefold increase year-over-year. Adjusted Net Income: $2.5 million, compared to a $59 million adjusted net loss a year ago. Adjusted Diluted Income Per Share: $0.01, compared to $0.15 for the same period last year. Cash Position: $949 million in cash equivalents and time deposits. Operating Cash Flow: $12 million in outlays, compared to $82 million in outlays for the same period last year. Carvicti Manufacturing Success Rate: 97% overall, with 99% success for patients with 1 to 3 prior lines of therapy. Carvicti Treatment Sites: 2
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech (LEGN) was upgraded by Truist Financial Corporation from "hold" to "strong-buy".MarketBeat
- Legend Biotech Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Legend Biotech (LEGN) had its price target lowered by Morgan Stanley from $50.00 to $49.00. They now have an "overweight" rating on the stock.MarketBeat
- Legend Biotech (LEGN) had its price target lowered by Royal Bank Of Canada from $66.00 to $62.00. They now have an "outperform" rating on the stock.MarketBeat
- Legend Biotech (LEGN) was given a new $70.00 price target by Truist Financial Corporation.MarketBeat
LEGN
Sec Filings
- 3/10/26 - Form 20-F
- 3/10/26 - Form 6-K
- 2/6/26 - Form 6-K
- LEGN's page on the SEC website